KRTL Biotech Showcases Gastrointestinal Health Portfolio to Address Global Demand for Accessible Digestive Care
- KRTL Biotech
- Oct 21
- 4 min read
The product line—developed and manufactured in collaboration with Industria Químico-Farmacéutica SIGMA Corp.—includes antacids, proton pump inhibitors, antidiarrheals, antiemetics, and oral rehydration therapies, all designed to meet the clinical and practical needs of pharmacies, public health systems, and hospital networks.
"Digestive care is a daily necessity for patients and providers alike," said Daniel Bishop, CEO of KRTL Biotech. "Our GI portfolio addresses everything from minor discomfort to acute dehydration, and these products are positioned for regional and global impact."
Key formulations include:
Omeprazole and Pantoprazole (acid reflux and GERD)
Aluminum hydroxide + magnesium combinations (antacid suspensions)
Loperamide and Racecadotril (antidiarrheals)
Simethicone and dimethicone (gas and bloating relief)
Electrolyte powders and oral hydration salts (rehydration)
Domperidone and metoclopramide (motility and nausea)
These products are manufactured under GMP-certified standards in Bolivia and are widely used across Latin America through both private and public channels. Several of these medications are included in national essential medicines lists and serve critical functions in pediatric, adult, and geriatric care.
"From pharmacies to emergency rooms, gastrointestinal therapies are essential in every healthcare environment," said Patricia Wilstermann, CEO of SIGMA. "We’ve built this line with both clinical consistency and broad accessibility in mind."
KRTL Biotech is currently reviewing potential U.S. and international regulatory designations for select GI products, including OTC Monograph eligibility and ANDA filings for prescription formulations. Certain hydration and antacid products may be prioritized for near-term export consideration due to their alignment with OTC use cases.
"Gastrointestinal health is a top-three pharmaceutical category globally," said Cesar Herrera, CEO of KRTL Holding Group Inc. "With SIGMA’s production expertise and KRTL Biotech’s international strategy, we are well-positioned to bring trusted digestive care products to new markets."
About KRTL Holding Group, Inc.
KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.
About KRTL Biotech, Inc.
KRTL Biotech, Inc., a 51% majority-owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), recently completed a merger with Industria Químico-Farmacéutica SIGMA Corp. S.R.L., integrating SIGMA’s decades of pharmaceutical expertise and infrastructure into KRTL’s international life sciences platform. This merger combines KRTL’s research, compliance, and global market access with SIGMA’s advanced Bolivian manufacturing capabilities, aligning both companies to deliver world-class pharmaceutical and nutraceutical solutions.
About Industria Químico Farmacéutica SIGMA Corp SRL
SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.
For more information:
Forward-Looking Statements
This press release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking statements” within the meaning of applicable securities legislation. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments and acquisitions; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company. Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law.
Comments